Oleoylethanolamide (OEA) – Kodiac biolabs

Our opinion on this compoundEstablished, active research

50/100

Canonical PPAR-alpha satiety probe with solid multi-lab rodent evidence but stalled clinical translation

Look, OEA is the kind of compound that earns its place in a research library for one specific reason: it’s the canonical probe for PPAR-alpha mediated satiety biology, and thats a real and underexplored axis. The Rodriguez de Fonseca group’s 2001 Nature paper established the basic story – small intestine synthesizes OEA in response to dietary fat, it binds PPAR-alpha with about 40 nM affinity, and signals fullness to the brain primarily through vagal afferents. That mechanism is genuinely distinct from leptin, ghrelin, and the peptide YY axis. If you’re investigating gut-brain satiety crosstalk and want a tool that isn’t just another CCK surrogate, OEA is the compound you reach for.

The rodent evidence base is solid and multi-lab. The mechanism is well-replicated across feeding behavior, lipid metabolism, and gut motility endpoints. Where OEA gets complicated is human translation – FAAH clears it fast enough that pharmacological administration of native OEA is a real pharmacokinetic problem. The short half-life isn’t fatal for bench work (you can probe endpoints in vitro and in acute animal models without worrying about trough levels), but it explains why clinical development stalled. Small human studies on OEA-based supplementation exist, but they haven’t produced the effect sizes that would move this into a different scoring tier.

What we like here is the mechanistic specificity. PPAR-alpha satiety signaling is genuinely separate from the GLP-1/GIP axis dominating metabolic pharmacology right now, and how these pathways interact is an active research question. OEA gives you a clean tool to probe the fatty acid-sensing arm of intestinal satiety signaling. That’s real value for anyone building experiments around feeding behavior or metabolic flexibility. The endocannabinoid-adjacent chemistry also makes it useful for investigating cross-talk with the AEA/CB1 axis without the receptor-binding confounds that come with direct cannabinoid tools.

What we dont love is that the novelty premium has worn off. The core mechanism has been known for over two decades. Clinical translation is hampered by PK, and nobody has solved that problem elegantly. OEA-content supplements are widely available commercially, which is a sourcing positive but also a clear signal that you’re not at the frontier anymore. It’s a mature, mechanistically interesting endogenous lipid mediator. For investigators focused on energy homeostasis, gut-brain axis signaling, or PPAR-alpha biology specifically, OEA earns its shelf space as the reference standard. Outside that specific program, it’s a second-tier priority.

Novelty: 40
Mechanism promise: 55
In-category differentiation: 58
Evidence quality: 50
Translational signal: 38
Research bench value: 65

Rationale OEA scores well on bench value as the reference probe for PPAR-alpha mediated gut-brain satiety signaling, but novelty is low after two decades of literature (mechanism characterized 2001), clinical translation is complicated by rapid FAAH-mediated clearance, and the compound occupies a well-defined niche rather than opening new territory.

Endogenous N-acylethanolamide (PPAR-alpha satiety signal)

An endogenous N-acylethanolamide; a PPAR-alpha agonist that signals satiety from the small intestine after fatty meals.

Abstract

Oleoylethanolamide (OEA; CAS 111-58-0; molecular formula C20H39NO2; molecular weight 325.53) is an endogenous N-acylethanolamide synthesized in the small intestine in response to dietary fat. The compound binds PPAR-alpha (Ki approximately 40 nM) with full agonist activity and signals satiety to the brain via vagal afferents and through direct CNS PPAR-alpha activation. The mechanism is distinct from leptin and ghrelin and represents a separate satiety pathway tied directly to fat intake. Pharmacological administration in rodents reduces food intake and body weight; clinical translation has been complicated by the short half-life (FAAH-mediated degradation). Used as the canonical PPAR-alpha satiety signal in metabolic and feeding research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-326Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.